U.S. Markets open in 7 hrs 7 mins

Recro Pharma eliminates 50 jobs following FDA setback

John George
Recro Pharma eliminates 50 jobs following FDA setback

Recro Pharma Inc. is eliminating about 50 positions in its acute care segment, and seeking a partner to commercialize its lead new drug candidate. Both moves come about two weeks after the Food and Drug Administration for a second time turned down the Malvern, Pa, pharmaceutical company's new drug application for intravenous meloxicam. Recro is seeking to market IV meloxicam, a non-opioid, as a treatment to manage moderate-to-severe pain.